ArticlePloS one2025
Association of serum iron status with MASLD and liver fibrosis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Mendelian Randomization Analysis of Systemic Iron Status and Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease.Metabolites · 2026Article
- Association of AGAHR with metabolic dysfunction-associated steatotic liver disease (MASLD).Hormones (Athens, Greece) · 2026Article
- Association Between Whole Blood Iron and Nonalcoholic Fatty Liver Disease in Elderly: A Case-Control Study.Biological trace element research · 2026Article
- Platelet-mediated progression of fatty liver disease in metabolic dysfunction-associated steatohepatitis: a pathophysiological review.Frontiers in medicine · 2026Review
- Effect of I Quit Ordinary Smoking (IQOS) Use on Hepcidin and Iron Parameters in Comparison with Conventional Smoking.Iranian journal of public health · 2025Article
- Hyperferritinemia and the Risk of Liver Fibrosis and Liver-Related Events in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe MASLD proposal updates and supplements the previous definition of NAFLD, making it more suitable for addressing the current understanding of chronic liver diseases. This study aims to investigate the potential association between serum iron status and the occurrence of MASLD and liver fibrosis.
methodsAn in-depth analysis was conducted using the 2017-2020 NHANES data. To assess the relationship between serum iron status and the prevalence of MASLD and liver fibrosis, we performed comprehensive data analysis. This approach accounts for multiple variables, enhancing the robustness and reliability of our results by reducing potential confounding factors.
resultsOur application of linear regression models provided significant insights through a comprehensive data analysis. Elevated serum ferritin, TIBC, and UIBC showed a distinct positive correlation with CAP, while only serum ferritin was positively correlated with LSM. Multivariate logistic regression analysis revealed that elevated levels of serum ferritin, TIBC, and UIBC were significantly associated with the occurrence of MASLD, whereas only serum ferritin showed a similar association with the occurrence of liver fibrosis.
conclusionThis study highlights the significant positive correlation between elevated levels of serum ferritin, TIBC, and UIBC with CAP and the prevalence of MASLD. A similar relationship was observed between serum ferritin with LSM and the prevalence of liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.